Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
about
Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response.Intermittent fasting promotes adipose thermogenesis and metabolic homeostasis via VEGF-mediated alternative activation of macrophage.Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients.Immunological landscape of consensus clusters in colorectal cancer.VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment.Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.Targeting VEGF receptors with non-neutralizing cyclopeptides for imaging applications.Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts.Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma.Targeting VEGF/VEGFR to Modulate Antitumor Immunity.Autoantigen-Harboring Apoptotic Cells Hijack the Coinhibitory Pathway of T Cell ActivationAdjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialEvaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors
P2860
Q33828636-15A5AF3E-DED4-4971-B9C1-BB07C197F812Q37509860-E1F20A59-5DD4-4042-9B80-12BDB97CA7DFQ41718028-72DD7435-AB6C-4810-82A3-854F60C46EBFQ45070266-DD21BCCE-A6E7-4BCD-B057-028548F59451Q47146356-B9059F4C-562D-471E-A719-0234050827AAQ47148210-9ECCBDE5-097E-4746-A91B-6EA4B26A530FQ47733010-79D3CC86-585D-4800-9791-2657A56BBC47Q48128395-B97CA223-6E6E-4D4C-80B0-BC32AB80B705Q49343443-67F656E7-58C8-44A3-9D70-652B0E7E93C0Q52353619-E3D2BA0A-79AC-4200-9FFD-60ED8318386AQ52717006-40050AD4-C9F9-49BC-AE76-D7FC700790CBQ53099936-D4EFF431-1E2D-416A-995F-1B8CD9DAD749Q55008337-1FBAD0CB-FA76-4954-961A-3066EB81D1CAQ57176332-5FEFCB09-F5A7-4077-8FC3-7516E2BE23BFQ57569466-599E7F98-3C39-454E-BB2A-6DC837A49A9CQ58696969-7FCE4205-DF66-4E7D-A69E-C93A603CE0C2
P2860
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
@en
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
@nl
type
label
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
@en
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
@nl
prefLabel
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
@en
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
@nl
P2093
P2860
P1476
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
@en
P2093
P2860
P304
P356
10.20892/J.ISSN.2095-3941.2015.0070
P577
2016-06-01T00:00:00Z